natgillin/translations-raw huggingface dataset:
The process of claim 1, wherein, the application method of the microwave power in said step b) is a continuous microwave mode or a combination of continuous microwave and pulse microwave modes; wherein, in case of using the combination of continuous microwave and pulse microwave, the continuous microwave irradiation is first used until the acid solution refluxes, and then is switched to pulse microwave for 5 to 120 minutes. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je način primjene snage mikrovalova u navedenom koraku 2) režim kontinuiranih mikrovalova ili kombinacija režima kontinuiranih mikrovalova i impulsa mikrovalova; gdje, u slučaju upotrebe kombinacije kontinuiranih mikrovalova i impulsa mikrovalova prvo se upotrebljava ozračivanje kontinuiranim mikrovalovima do refluksa otopine kiseline, a zatim se prebaci na impuls mikrovalova u trajanju od 5 minuta do 120 minuta.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1 or 2, wherein optionally said antigen-presenting cell comprises an expression vector expressing said peptide according to claim 1 or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limfocita (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2. Metoda u skladu s patentnim zahtjevom 9, pri čemu stanica koja prezentira antigen sadrži vektor ekspresije koji eksprimira navedeni peptid u skladu sa zahtjevom 1 ili 2.
None of the prior art discloses 4-(2,3-dihalogenoanilino)quinazoline or 4-(2,3,4-trihalogenoanilino)quinazoline compounds. 
U niti jednom stanju tehnike nisu objavljeni spojevi 4-(2,3-dihalogenoanilino)kinazolina ili 4-(2,3,4-trihalogenoanilino)kinazolina.
The binding molecule can be a naked or unconjugated binding molecule but can also be part of an immunoconjugate. 
Molekula za vezanje u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da je molekula za vezanje IgG.
The assembly of claim 1, wherein said first interlocking assembly further comprises at least one ramp extending at least partially circumferentially around said round section, said ramp sloping from a position proximate the end of said first interlocking assembly that receives said second interlocking assembly (which end is considered as its top), to a position beneath said first interlock piece (relative to said top). 
Sklop (1) prema zahtjevu 4 ili 5, gdje prvi zaporni sklop nadalje obuhvaća barem jednu kosinu (11) koja se pruža barem djelomično periferno oko okruglog segmenta, kosina (11) se spušta s položaja blizu kraja prvog zapornog sklopa koji prima drugi zaporni sklop, čiji kraj se smatra njegovim vrhom, do položaja ispod prvog zapornog komada, u odnosu na vrh.
The pharmaceutical composition according to claim 8 wherein the pharmaceutically acceptable salt of a compound of formula (I) is a sodium salt. 
Kombinacija u skladu s patentnim zahtjevom 1, naznačena time što je farmaceutski prihvatljiva sol spoja formule (I) natrijeva sol.
A process according to any one of the claims 1 to 8, characterised in that at least 75 wt. %, preferably at least 90 wt. of said foamable composition (7) is applied by spraying it onto the core layer (1) while holding the core layer (1) in said lying position. 
Postupak prema jednom od zahtjeva 1 do 9, naznačen time da najmanje 75 tež.% pjenastog sastava (7) bude naneseno sprejanjem jezgrenog sloja (1), tijekom kojeg jezgreni sloj (1) bude držan u ležećem položaju.
Systems and methods for generating and maintaining an HPF regime FRC have been disclosed. 
Postupak za generiranje i održavanje magnetskog polja s konfiguracijom povratnog polja FRC (engl.
contacting a compound which stimulates functionality of the receptor in step (b) in vitro with a mammalian enteroendocrine cell; and 
(c) stavljanje u kontakt spoja koji stimulira funkcionalnost receptora u koraku (b) in vitro s enteroendokrinom stanicom sisavca, te
from about 40% to about 75% by weight of microcrystalline cellulose; 
(c) od 40% do 75% težinski mikrokristalinične celuloze;
They were designated IL-18BP a, b, c, and d, all sharing the same N-terminus and differing in the C-terminus (Novick et al 1999). 
Označeni su kao IL-18BP a, b, c i d, a sve imaju isti N-kraj i različit C-kraj (Novick i sur., 1999).
The benefits of nicotinic acid in the treatment or prevention of atherosclerotic cardiovascular disease have been documented in six major clinical trials [Guyton JR (1998) Am J Cardiol 82:18U-23U]. 
Povoljno djelovanje nikotinske kiseline u liječenju ili prevenciji aterosklerotičnih kardiovaskularnih oboljenja je bilo dokumentirano u šest glavnih kliničkih ispitivanja [Guyton JR (1998) Am J Cardiol 82:18U-23U].
Cells are washed 4 times with wash buffer (Hanks balanced salt, 20 mM HEPES, 2.5 mM probenecid) after loading, leaving 150 ul in the well after the last wash. 
Stanice su isprane 4 puta puferom za ispiranje (Hanksova uravnotežena sol, 20 mM HEPES, 2,5 mM probenecid) nakon prebacivanja, a u jažici je ostalo 150 ul nakon posljednjeg ispiranja.
checking that no alert has already been sent; closing alert steps wherein the connected device cuts off water at the outlet and transmit a closing alert over the system network before ending the method; 
• korake (13-5, 13-6) koji omogućuju priključenom uređaju da isključi vodu na izlazu i pošalje upozorenje o isključenju u mrežu sustava prije završavanja postupka;
The medicament for use according to any one of claims 1, 3 or 4, wherein the medicament is a pharmaceutical composition in the form of a sterile solution. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da čovjek kao pacijent nije primio terapiju glatiramer acetatom prije početka liječenja.
It would be desirable to develop potent inhibitors of GST P1-1 for use in humans to: potentiate the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exert cytotoxicity in tumor cells, elevate the production of GM progenitors in bone marrow, stimulate the differentiation of bone marrow, mitigate the myelosuppressive effects of chemotherapeutic agents, and modulate hematopoiesis in bone marrow. 
Bilo bi poželjno razviti jake inhibitore GST P1-1 za upotrebu kod čovjeka za: pojačavanje utjecaja kemoterapijskih agenasa u stanicama tumora, selektivni utjecaj citotoksiciteta u stanicama tumora, povećati produkciji GM progenitora u koštanoj srži, stimulirati diferencijaciju koštane srži, ublažiti mielosupresivne efekte kemoterapijskih agensa, 1 modulirati hematopoiesis u koštanoj srži.
The coated panel of claim 8, wherein said modified clay is one of a modified smectite clay, a modified hydrous sodium lithium magnesium silicate and mixtures thereof. 
Obložena ploča iz zahtjeva 8, naznačena time što je modificirana glina modificirana smektitna glina, modificirani vodeni natrijev litijev magnezijev silikat i njihove mješavine.
the compound (XXV) is then subjected to a condensation reaction with an alkyl or aryl anhydride (Rb'CO)2O, Rb' being as defined in Claim 1, in order to obtain the compound of formula (XVIII): 
spoj (XXV) se zatim podvrgava reakciji kondenzacije sa alkil ili aril anhidridom (Rb'CO)2O, Rb' je kako je definirano u zahtjevu 1, kako bi se dobilo spoj s formulom (XVIII): [image]
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbomen-5-il)amid, a kao komponentu (B) klorotalonil.
The garden water hose assembly (10) of Claim 1, wherein the outer tube (12) of the hose assembly (10) is soft, bendable and is capable of withstanding internal pressures of up to 17.24 bar (250 pounds per square inch). 
Sklop cijevi za zalijevanje vrta (10) prema zahtjevu 1, naznačen time, da je vanjska cijev (12) sklopa cijevi (10) mekana, savitljiva 1 sposobna je podnijeti unutarnje pritiske do 17,24 bara (250 funti po kvadratnom inču).
(viii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 120 and the light chain comprises an amino acid sequence represented by SEQ ID NO: 128, and 
sekvence nukleinske kiseline koja kodira polipeptid koji sadrži varijabilno područje teškog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 134 i varijabilno područje lakog lanca koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 140;
said monoclonal antibody is an anti-EGFR monoclonal antibody when the subject has EGFR-expressing, metastatic colorectal carcinoma, EGFR-expressing head and neck cancer or KRAS mutant cancer. 
je spomenuto monoklonsko protutijelo anti-EGFR monoklonsko protutijelo kada subjekt ima s EGFR povezanu ekspresiju, metastazni kolorektalni karcinom, s ekspresijom EGFR povezanu karcinom glave i vrata ili KRAS mutant karcinom.
The cavity of the floating element may be filled with a buoyancy material. 
PLUTAJUĆI ELEMENT I POSTUPAK OBLIKOVANJA SUSTAVA UZGONA
The invention provides a composition for admixture with water, wherein the composition is optionally presented in two or more parts and comprises: to 400 mmol ascorbate anion provided by a mixture of: ascorbic acid and 
Pripravak namijenjen miješanju s vodom, naznačen time što pripravak može biti prisutan u dva ili više dijelova 1 sadrži: a) 150 do 400 mmol askorbatnog aniona kojeg osigurava smjesa:
a nucleic acid sequence encoding heavy chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 45-52, positions 70-77, and positions 116-124 of SEQ ID NO: 117, respectively; and a nucleic acid sequence encoding light chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 47-52, positions 70-72, and positions 109-117 of SEQ ID NO: 123, respectively; 
sekvencu nukelinske kiseline koja kodira polipeptid koji sadrži varijabilno područje teškog lanca protutijela (VH) koji sadrži CDR1, CDR2, i CDR3 područja koja sadrže aminokiselinske sekvence položaja 45-52, položaja 70-77, i položaja 116-124 od SEQ ID NO: 117, respektivno; i sekvencu nukleinske kiseline koja kodira polipeptid koji sadrži varijabilni područje lakog lanca protutijela (VL) koji sadrži CDR1, CDR2, i CDR3 područje koje sadrži aminokiselinske sekvence položaja 47-52, položaja 70-72, i položaja 109-117 od SEQ ID NO: 123, respektivno; ili
The self-tapping screw according to claims 1 to 5, characterized in that it has two threaded portions (117, 117a) which are mutually spaced, each one for a corresponding hole (118, 118a) of a corresponding metallic layer. 
Samonarezni vijak prema zahtjevima 1 do 3, naznačen time da ima dva dijela s navojem (117, 117a) koji su međusobno razmaknuti, svaki za odgovarajući otvor (118, 118a) odgovarajućeg metalnog sloja.
This blend is heated at 190-270°C for 0.5-8 hours when chemical degradation takes place, then it is cooled down to 160-190°C and high shear mixing is applied for 0.25-4 hours. 
- mješavina se zagrijava na 190-270 "C tijekom 0,5-8 sati, kada se odvija kemijska degradacija, - tada se hladi do 160-190 "C, te se - zatim se snažno miješa uz visoku smičnost tijekom 0,25-4 gata,
The artemisinin compound for use according to claim 1 or 2, wherein the compound is administered to the patient in a therapeutically effective amount to treat hypoinsulinemia, preferably by systemic or local administration. 
Spoj artemizinina namijenjen upotrebi u skladu sa zahtjevom 1 ili 2, naznačen time što se spoj primjenjuje na pacijentu u terapijski djelotvornoj količini za liječenje hipoinzulinemije, po mogućnosti sistemnom ili lokalnom primjenom.
An oral formulation in tablet form according to claim 1, wherein the tablet further comprises a glidant. 
Oralna formulacija u obliku tablete u skladu s patentnim zahtjevom 1, naznačena time što tableta dodatno sadrži sredstvo za klizanje.
For those reasons, the colon is the sector of the intestine most susceptible to infection; in fact, infections located in the colon (infectious colitis, bacillary dysentery, diarrhoea, pseudomembranous colitis, diverticulitis, etc.) 
Iz tih je razloga kolon dio crijeva koje je najpodložnije infekcijama; naime infekcije smještene u kolonu (infektivni kolitis, bacilarna dizenterija, dijareja, pseudomembranski kolitis, divertikulitis, itd.)
A light source as claimed in claim 1, claim 2 or claim 3, wherein the plasma crucible is of circular cross-section and is dimensioned for a half wave to extend diametrically within it. 
Svjetlosni izvor u skladu s onim iz patentnog zahtjeva 1, patentnog zahtjeva 2 ili patentnog zahtjeva 3, naznačen time, da plazmena retorta ima kružni poprečni presjek i dimenzije koje omogućuju da se poluval širi dijametralnu unutarnje.
In some embodiments the element may be replaced while in others it is not possible to replace the element. 
U nekim ostvarenjima element se može vratiti na staro mjesto dok u drugima nije moguće vratiti element na staro mjesto.
In another embodiment, the persisting population of genetically engineered T cells persists in the human for at least four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, two years, or three years after administration. In one embodiment, the chronic lymphocytic leukemia is treated. 
T stanica za upotrebu prema patentnom zahtjevu 10, naznačena time što primijenjena genetički konstruirana T stanica proizvodi populaciju potomstva T stanica koja perzistira u čovjeku najmanje tri mjeseca, četiri mjeseca, pet mjeseci, šest mjeseci, sedam mjeseci, osam mjeseci, devet mjeseci, deset mjeseci, jedanaest mjeseci, dvanaest mjeseci, dvije godine, ili tri godine nakon primjene.
(A2a) a phenyl-substituted lower alkenyl group having a halogen-substituted lower alkoxy group(s) as a substituent(s) on a phenyl group, or 
(A2a) fenil-supstituiranu skupinu niži alkenil s halogen-supstituiranom skupinom (skupinama) niži alkil kao supstituentom (s) na fenilnoj skupini, ili
A compound represented by any any one of the structural formulas set forth below: 
Spoj prema zahtjevu 1 predstavljen bilo kojom od strukturnih formula navedenih ispod:
A combination according to claim 1 wherein the antagonist of M3 muscarinic receptor (b) is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane bromide. 
Kombinacija u skladu s patentnim zahtjevom 1, naznačena time, da antagonist M3 muskarinskog receptora (b) jeste (3R)-1-feniletil-3(9H-ksanten-9-karboniloksi)-! -azoniabiciklo[2.2.2]oktan bromid.
The method according to claim 15, wherein the positive control or calibration samples are used to identify and compensate for variations due to different reagent activities. 
Postupak u skladu s patentnim zahtjevom 15, naznačen time, da se uzorci za pozitivnu kontrolu ili kalibracijski uzorci koriste za identifikaciju i kompenziranje varijacije zbog različitih aktivnosti reagensa.
it has an increased activity and/or increased yield compared to at least one antibody molecule composition of the same antibody molecule when expressed in the cell line ATCC No. 
- ima povišenu aktivnost i/ili povećani prinos u usporedbi s pripravkom s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
A method of preparing an alcohol solvate of the sodium salt of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid comprising the steps of: 
Postupak za proizvodnju alkoholnog solvata natrijeve soli ud (S)-2-(difenilacetil)- 1,2,3,4-tetrahidro-6-metoksi-5-(fenilmetoksi)-3-izokinolin-karboksilne kiseline, naznačen time, da obuhvaća sljedeće korake:
Rd and Re, are chosen independently from the group consisting of hydrogen, hydroxy, C1-4alkoxy or together with the pertaining C-atoms represent 1,3-dioxolane ring which can be additionally alkyl or alkenyl mono or di-substituted; and Rj is chosen from the group consisting of hydrogen and chlorine; 
RÅ i Rč se neovisno bira iz skupine koju čine vodik, hidroksi, C;-galkoksi, ili, zajedno s pripadajućim C-atomima, predstavlja 1,3-dioksolanski prsten, koji može biti daljnje mono- ili disupstituiran s alkilom ili alkenilom; i R! se bira iz skupine koju čine vodik i klor; gdje
g (0.42 mmol) of N-methylmorpholine N-oxide, 0.001 g (0.0014 mmol) of tetra-n-propylammonium perruthenate and 1 g of powdered molecular sieves (4A) were added and the mixture was stirred at 20° C. under nitrogen atmosphere for 3 h. 
Doda se 0,049 g (0,42 mmol) N-metilmorfolin-Noksida, 0,001 g (0,0014 mmol) tetra-n-propilamonijevog perrutenata i 1 g molekulskih sita u prahu (4 A), a smjesu miješa 3 sata na 20 *C u atmosferi dušika.
At least one compound of any one of claims 1 or 2, and/or at least one pharmaceutically acceptable salt thereof, wherein Y is absent. 
Spoj prema zahtjevu 1 naznačen time da je: [image] i/ili najmanje jedna njegova farmaceutski prihvatljiva sol.
The resulting solid was washed with Pet ether (2×100 mL), and dried to give the second crop m=6.0 g. 
Dobivena se krutina ispere s petroleterom (2x100 mL) i osuši da se dobije drugi prinos m = 6,0 g.
The retinal derivative for use according to claim 2, which is a 9- cis- retinyl ester of a C1 to C10 monocarboxylate. 
Derivat retinala za upotrebu u skladu s patentnim zahtjevom 2, naznačen time, da je to 9-cis-retinil ester C1-C10 monokarboksilata.
A pharmaceutical composition for use in the treatment of aqueous or evaporative dry eye disease, a condition that is associated with or causes aqueous or evaporative dry eye disease, or symptoms associated therewith in an individual, the composition being suitable for topical application to an ocular surface, and comprising a therapeutically effective concentration of PRG4 suspended in an ophthalmically acceptable balanced salt solution. 
Farmaceutski oblik za uporabu u liječenju vodene ili isparavajuće bolesti suhog oka, stanja koja su povezana s ili uzrokuju vodenu ili isparavajuću bolest suhog oka, ili s njima povezanih simptoma, u pojedinca, oblik je prikladan za topikalnu primjenu na površinu oka, sadrži terapijski učinkovitu koncentraciju PRG4 suspendiranog u oftalmički prikladnoj uravnoteženoj fiziološkoj otopini.
The antibody or antigen-binding fragment thereof of any one of claims 3-5, wherein, the antibody or antigen-binding fragment thereof is an antagonist of Sp35-mediated neurite outgrowth inhibition, an antagonist of Sp35-mediated myelination inhibition, or an antagonist of Sp35-mediated oligodendrocyte differentiation inhibition. 
Antitijelo ili antigen vezujući fragment istog iz zahtjeva 1, pri čemu je antitijelo ili antigen vezujući fragment istog antagonist Sp35-posredovane inhibicije izrastanja neurita, antagonist Sp35-posredovane inhibicije mijelinizacije, ili antagonist Sp35-posredovane inhibicije diferencijacije oligodendrocita.
Figure 35 is a diagram of an exemplary 7,9-acetalization of the compound formed in Figure 34. 
Slika 35 je grafički prikaz primjera 7,9-acetalizacije spoja dobivenog na slici 34.
The process of claim 20, wherein the hydroconversion reactor comprises at least one of a fixed-bed vacuum gas oil (VGO) hydrocracking reactor system, a fluidized bed VGO hydrocracking reactor system. 
Sustav u skladu s patentnim zahtjevom 17, naznačen time, da reaktor za hidrokonverziju (94) sadržava reaktorski sustav za hidrokrekiranje VGO s fiksnim slojem i hidrokreking reaktorski sustav za hidrokrekiranje VGO s fluidiziranim slojem.
or a pharmaceutically acceptable salt or ester, thereof; wherein: 
Formula NI ili njegova farmaceutski prihvatljiva sol ili ester; naznačen time, da:
The multivalent antibody of claim 1, wherein the first target binding site comprises residues 24-34 of SEQ ID NO: 84 for CDR-L1, residues 50-56 of SEQ ID NO: 84 for CDR-L2, residues 89-97 of SEQ ID NO: 84 for CDR-L3, residues 31-35 of SEQ ID NO: 85 for CDR-H1, residues 50-65 of SEQ ID NO: 85 for CDR-H2, and residues 95-102 of SEQ ID NO: 85 for CDR-H3, wherein the residues are numbered according to Kabat. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 7, naznačen time, da protutijelo anti-DLL3 obuhvaća ostatke od 30 do 36 od SEQ ID NO:60 za CDR-L1, ostatke od 46 do 55 od SEQ ID NO:60 za CDR-L2, ostatke od 89 do 96 od SEQ ID NO:60 za CDR-L3, ostatke od 30 do 35 od SEQ ID NO:61 za CDR-HI, ostatke od 47 do 58 od SEQ ID NO:61 za CDR-H2 1 ostatke od 93 do 101 od SEQ ID NO:61 za CDR-H3, pri čemu su ostatci numerirani prema sustavu MacCallum.
The compound of claim 9, wherein Ra is H or alkyl. The compound of claim 10, wherein Rx is alkyl. 
Spoj of any of patentni zahtjevi 9 ili 10, naznačen time što Ra je H ili C1-C10 alkil.
an immunoglobulin heavy chain variable domain (VH) which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence SEQ ID NO:1, said CDR2 having the amino acid sequence SEQ ID NO:2, and said CDR3 having the amino acid sequence SEQ ID NO:3 or direct CDR equivalents thereof; and 
VH koji obuhvaća u nizu hipervarijabilna područja CDR1, CDR2 i CDR3, gdje navedeno područje CDR1 ima aminokiselinsku sekvencu SEQ ID NO:1, navedeno područje CDR2 ima aminokiselinsku sekvencu SEQ ID NO:2, i navedeno područje CDR3 ima aminokiselinsku sekvencu SEQ ID NO:3, dok su hipervarijabilna područja određena prema Kabat-definiciji; ili
In additional embodiments, the external aqueous phase comprises a surfactant selected from polyvinyl alcohol (PVA), polysorbate, polyethylene oxide-polypropylene oxide block copolymers and cellulose esters. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da vanjska vodena faza sadrži surfaktant izabran između polivinil alkohola (PVA), polisorbata, polietilena oksid-polipropilen oksid blok kopolimeri i celulozni esteri.
The material according to anyone of claims 1-4 wherein the preferred thread density of the glass fibre is 5 to 250 threads per cm, especially from 20 to 60 threads per cm. 
Materijal temeljem bilo kojeg zahtjeva od 1 do 4 naznačen time da je poželjna debljina niti staklenog vlakna od 5 do 250 niti po cm, posebno od 20 do 60 niti po cm.
Cell density was measured using a haemocytometer and viability was calculated using Trypan Blue solution before being further diluted in Growth Medium and seeded at a density of 1x104 cells per well (in 100ul) into clear bottomed 96 well plates (Packard, No. 
Gustoća stanica izmjeri se hemocitometrom i vijabilnost izračuna koristeći otopinu Tripan-plavo prije daljnjeg razrijeđivanja u hranjivom mediju i nasađivanja u mikrotitarske pločice sa prozirnim dnom (Packard, No.
When the supercritical extraction is performed in two steps, first with carbon dioxide and then with a combination of carbon dioxide and ethanol, as the fat fraction a lipid concentrate is obtained containing more than 90% polar lipids preferably comprising 35 to 50%, typically about 40% phospholipids, and preferably 50 to 70%, typically about 60% glycolipids. 
Postupak prema zahljevu 1, naznačen time što frakcije masti dobivene super-kritičnom ekstrakcijom sadrže lipidima obogaćeno zobeno ulje sa sadržajem neutralnih masti većim od 90% koji obuhvaća trigliceride i/ili lipidima obogaćeno zobeno ulje sa sadržajem polarnih lipida većim od 90%, poželjno s 35 do 50% fosfolipida, i poželjno 50 do 70% glikolipida.
The method of claim 1, wherein a second MACERS that is increased as compared to the first MACERS indicates that the subject's condition is declining. 
Metoda zahtjeva 7, pri čemu je tretman određen kao neefikasan kod pacijenta koji ima drugi MACERS jednak ili uvećan u usporedbi sa prvim MACERS.